Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses
The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age o...
Gespeichert in:
Veröffentlicht in: | The Annals of thoracic surgery 1995-08, Vol.60 (2 Suppl), p.S470-S474 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S474 |
---|---|
container_issue | 2 Suppl |
container_start_page | S470 |
container_title | The Annals of thoracic surgery |
container_volume | 60 |
creator | Ian Munro, A. Eric Jamieson, W.R. Frank, G. Tyers, O. Germann, Eva |
description | The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p < 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prost |
doi_str_mv | 10.1016/0003-4975(95)00271-L |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77458212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>000349759500271L</els_id><sourcerecordid>77458212</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</originalsourceid><addsrcrecordid>eNp9kMtKxDAUhoMo4zj6BgpdiS6qSdqkrQtBBm9Q0MW4DmlywkR6M2kLvr0ZZxh3rg7n_P-5fQidE3xDMOG3GOMkTouMXRXsGmOakbg8QHPCGI05ZcUhmu8tx-jE-8-Q0iDP0CzjKacEz1G5claNvrc6mmQ9QeSgr6WCBtrhLnrvnLItRJXtetf5YQ0efCRbHTWg1rK1StbRn3KKjoysPZzt4gJ9PD2uli9x-fb8unwoY5WwbIgJZVJjygtmSFUQk6tcmqoioBjRBoAVRuYm0RVOeUgqnQDnkjMT6sGgkwW63M4Nq79G8INorFdQ17KFbvQiy1KWU0KDMd0aVbjROzCid7aR7lsQLDYQxYaQ2BASBRO_EEUZ2i5288eqAb1v2lEL-v1Wh_DkZMEJryy0CrR1oAahO_v_gh8804Mi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77458212</pqid></control><display><type>article</type><title>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><source>Alma/SFX Local Collection</source><creator>Ian Munro, A. ; Eric Jamieson, W.R. ; Frank, G. ; Tyers, O. ; Germann, Eva</creator><creatorcontrib>Ian Munro, A. ; Eric Jamieson, W.R. ; Frank, G. ; Tyers, O. ; Germann, Eva</creatorcontrib><description>The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p < 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prostheses was 88.9% ± 10.5% at 5 and 7 years and for bioprostheses, it was 100% at both times (p = not significant). Tricuspid valve replacement carries a high early and late mortality rate. Bioprostheses are recommended because of the low rate of structural valve deterioration and avoidance of thrombosis.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/0003-4975(95)00271-L</identifier><identifier>PMID: 7646210</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Actuarial Analysis ; Bioprosthesis - adverse effects ; Bioprosthesis - mortality ; Female ; Heart Valve Prosthesis - adverse effects ; Heart Valve Prosthesis - mortality ; Humans ; Male ; Middle Aged ; Reoperation ; Survival Rate ; Thrombosis - etiology ; Tricuspid Valve - surgery</subject><ispartof>The Annals of thoracic surgery, 1995-08, Vol.60 (2 Suppl), p.S470-S474</ispartof><rights>1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</citedby><cites>FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0003-4975(95)00271-L$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7646210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ian Munro, A.</creatorcontrib><creatorcontrib>Eric Jamieson, W.R.</creatorcontrib><creatorcontrib>Frank, G.</creatorcontrib><creatorcontrib>Tyers, O.</creatorcontrib><creatorcontrib>Germann, Eva</creatorcontrib><title>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p < 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prostheses was 88.9% ± 10.5% at 5 and 7 years and for bioprostheses, it was 100% at both times (p = not significant). Tricuspid valve replacement carries a high early and late mortality rate. Bioprostheses are recommended because of the low rate of structural valve deterioration and avoidance of thrombosis.</description><subject>Actuarial Analysis</subject><subject>Bioprosthesis - adverse effects</subject><subject>Bioprosthesis - mortality</subject><subject>Female</subject><subject>Heart Valve Prosthesis - adverse effects</subject><subject>Heart Valve Prosthesis - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Reoperation</subject><subject>Survival Rate</subject><subject>Thrombosis - etiology</subject><subject>Tricuspid Valve - surgery</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKxDAUhoMo4zj6BgpdiS6qSdqkrQtBBm9Q0MW4DmlywkR6M2kLvr0ZZxh3rg7n_P-5fQidE3xDMOG3GOMkTouMXRXsGmOakbg8QHPCGI05ZcUhmu8tx-jE-8-Q0iDP0CzjKacEz1G5claNvrc6mmQ9QeSgr6WCBtrhLnrvnLItRJXtetf5YQ0efCRbHTWg1rK1StbRn3KKjoysPZzt4gJ9PD2uli9x-fb8unwoY5WwbIgJZVJjygtmSFUQk6tcmqoioBjRBoAVRuYm0RVOeUgqnQDnkjMT6sGgkwW63M4Nq79G8INorFdQ17KFbvQiy1KWU0KDMd0aVbjROzCid7aR7lsQLDYQxYaQ2BASBRO_EEUZ2i5288eqAb1v2lEL-v1Wh_DkZMEJryy0CrR1oAahO_v_gh8804Mi</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>Ian Munro, A.</creator><creator>Eric Jamieson, W.R.</creator><creator>Frank, G.</creator><creator>Tyers, O.</creator><creator>Germann, Eva</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</title><author>Ian Munro, A. ; Eric Jamieson, W.R. ; Frank, G. ; Tyers, O. ; Germann, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-125ad02695f1b91f8c8afbb1ec51dfee59fa8f3db046e59bd3e66a65f9fa1dfd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Actuarial Analysis</topic><topic>Bioprosthesis - adverse effects</topic><topic>Bioprosthesis - mortality</topic><topic>Female</topic><topic>Heart Valve Prosthesis - adverse effects</topic><topic>Heart Valve Prosthesis - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Reoperation</topic><topic>Survival Rate</topic><topic>Thrombosis - etiology</topic><topic>Tricuspid Valve - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ian Munro, A.</creatorcontrib><creatorcontrib>Eric Jamieson, W.R.</creatorcontrib><creatorcontrib>Frank, G.</creatorcontrib><creatorcontrib>Tyers, O.</creatorcontrib><creatorcontrib>Germann, Eva</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ian Munro, A.</au><au>Eric Jamieson, W.R.</au><au>Frank, G.</au><au>Tyers, O.</au><au>Germann, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>60</volume><issue>2 Suppl</issue><spage>S470</spage><epage>S474</epage><pages>S470-S474</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><abstract>The clinical performance of tricuspid valve replacement with bioprostheses and mechanical prostheses was assessed in a series of 5,489 total valve replacement operations performed from 1975 to 1992. There were 97 (1.8%) tricuspid valve replacements in 94 patients (16 men, 78 women) with a mean age of 55.4 ± 13.8 years. Bioprostheses (mean patient age, 55.9 ± 14.1 years) were used in 83 operations and mechanical prostheses (mean patient age, 52.1 ± 11.9 years) were used in 14 operations. There were 30 isolated tricuspid valve replacements and 67 tricuspid valve replacements incorporated in multiple valve replacements. The total cumulative follow-up was 360 patient-years (bioprostheses, 321 years; mechanical prostheses, 39 years) (96.8% complete). The mean follow-up was 3.7 years (bioprostheses, 3.9 years; mechanical prostheses, 2.8 years) (p = not significant). The early mortality was 14.4% (bioprostheses, 14.5%; mechanical prostheses, 14.3%) (p = not significant) (isolated replacement, 13.3%; multiple replacement, 14.9%). The late mortality was 9.2% per patient-year (isolated replacement, 12.2% per patient-year; multiple replacement, 7.9% per patient-year). The freedom from structural valve deterioration at 5 and 7 years was 100% for mechanical prostheses and 97.1% ± 2.9% for bioprostheses (p = not significant). For isolated tricuspid valve replacement, the freedom from structural valve deterioration for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). For the mechanical prostheses, the freedom was 100%. The freedom from valve-related reoperation for mechanical prostheses was 86.7% ± 12.4% at 5 and 7 years; for bioprostheses, it was 97.1% ± 2.9% at 5 years and 92.5% ± 5.2% at 7 years (p = not significant). There was one reoperation among the isolated replacements with bioprostheses (one of four), and freedom from reoperation for bioprostheses was 90.9% ± 8.7% at 5 years and at 7 years (p = not significant). With multiple tricuspid valve replacement, the freedom from reoperation for mechanical prostheses was 84.6% ± 14.2% at 5 and 7 years; for bioprostheses, it was 100% at 5 years and 93.8% ± 6.1% at 7 years (p = not significant). Thrombosis was different (p < 0.05): for overall tricuspid valve replacement, the freedom from thrombosis for mechanical prostheses was 90.9% ± 8.7% at 5 and 7 years and for bioprostheses, it was 100%. In the tricuspid valve multiple replacement group, the freedom from thrombosis for mechanical prostheses was 88.9% ± 10.5% at 5 and 7 years and for bioprostheses, it was 100% at both times (p = not significant). Tricuspid valve replacement carries a high early and late mortality rate. Bioprostheses are recommended because of the low rate of structural valve deterioration and avoidance of thrombosis.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>7646210</pmid><doi>10.1016/0003-4975(95)00271-L</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4975 |
ispartof | The Annals of thoracic surgery, 1995-08, Vol.60 (2 Suppl), p.S470-S474 |
issn | 0003-4975 1552-6259 |
language | eng |
recordid | cdi_proquest_miscellaneous_77458212 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier); Alma/SFX Local Collection |
subjects | Actuarial Analysis Bioprosthesis - adverse effects Bioprosthesis - mortality Female Heart Valve Prosthesis - adverse effects Heart Valve Prosthesis - mortality Humans Male Middle Aged Reoperation Survival Rate Thrombosis - etiology Tricuspid Valve - surgery |
title | Tricuspid valve replacement: Porcine bioprostheses and mechanical prostheses |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T08%3A23%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tricuspid%20valve%20replacement:%20Porcine%20bioprostheses%20and%20mechanical%20prostheses&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=Ian%20Munro,%20A.&rft.date=1995-08-01&rft.volume=60&rft.issue=2%20Suppl&rft.spage=S470&rft.epage=S474&rft.pages=S470-S474&rft.issn=0003-4975&rft.eissn=1552-6259&rft_id=info:doi/10.1016/0003-4975(95)00271-L&rft_dat=%3Cproquest_cross%3E77458212%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77458212&rft_id=info:pmid/7646210&rft_els_id=000349759500271L&rfr_iscdi=true |